A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

Who May Qualify: 1. Aged 18 to 65 years at the time of consent. 2. Diagnosis of SLE according to the 2019 European League Against. Rheumatism and the American College of Rheumatology (ACR) classification criteria. 3. Active, seropositive disease, with SLEDAI 2K \>=8. 4. Inadequate response to at least 2 therapeutic interventions, including at least one oral immunosuppressive or biologic standard-of care therapy. Who Should NOT Join This Trial: 1. Active neuropsychiatric SLE. 2. History of inflammatory or autoimmune conditions (where your immune system attacks your own body)s including, but not limited to, rheumatoid arthritis, scleroderma, myositis, vasculitis, inflammatory bowel disease, or other conditions that require immune suppressive therapy. Subjects with stable concurrent Sjogren's, asthma, or autoimmune thyroid disease may be considered for participation. 3. Active systemic infection or history of chronic, recurrent, latent, or recent serious infections. Always talk to your doctor about whether this trial is right for you.